Recent topics related to testosterone deficiency syndrome in Japan

Asian Journal of Andrology

Volumn 13, Issue 4, 2011, Pages 558-562

  Tsujimura, Akira ^a   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

herbal medicine; hormone replacement therapy; metabolic syndrome; testosterone deficiency syndrome

Indexed keywords

ADIPONECTIN; BU ZHONG YI QI TANG; CHORIONIC GONADOTROPIN; CYTOKINE; GAMMA INTERFERON; GLOWMIN; HACHIMIJIOGAN; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; INTERLEUKIN 13; INTERLEUKIN 8; KAMISHOYOSAN; KAVA EXTRACT; KEISHI BUKURYO GAN; METHYLTESTOSTERONE; SAIKO KA RYUKOTSU BOREI TO; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; TESTOSTERONE UNDECANOATE; TOKISHAKUYAKU SAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGING; ANDROGEN DEFICIENCY; ANXIETY DISORDER; CLINICAL PRACTICE; CYTOKINE PRODUCTION; DEPRESSION; DIARRHEA; DRUG EFFICACY; ERECTILE DYSFUNCTION; GEL; HERBAL MEDICINE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INJECTION; JAPAN; JAPANESE; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; NAUSEA; OINTMENT; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEXUAL FUNCTION; SYMPTOM; SYNDROME DELINEATION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADIPONECTIN; DRUGS, CHINESE HERBAL; HERBAL MEDICINE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; JAPAN; MALE; METABOLIC SYNDROME X; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE;

EID: 79960046175     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.132     Document Type: Review

References (90)

1. Morales A, Schulman CC, Tostain J, Wu FC. Testosterone deficiency syndrome (TDS) needs to be named appropriately-the importance of accurate terminology. Eur Urol 2006; 50: 407-9. (Pubitemid 44192565)
2. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM et al. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004; 1: 69-81. (Pubitemid 40424669)
3. Morales A, Heaton JP, Carson CC 3rd. Andropause: a misnomer for a true clinical entity. J Urol 2000; 163: 705-12. (Pubitemid 30091601)
4. Morley JE. Androgens and aging. Maturitas 2001; 38: 61-71.
5. Morley JE, Perry HM 3rd. Androgen deficiency in aging men. Med Clin North Am 1999; 83: 1279-89. (Pubitemid 29430379)
6. Vermeulen A. Andropause. Maturitas 2000; 34: 5-15. (Pubitemid 30015982)
7. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-5. (Pubitemid 44232378)
8. Namiki M, Akaza H, Shimazui T, Ito N, Iwamoto T et al. Clinical practice manual for late-onset hypogonadism syndrome. Int J Urol 2008; 15: 377-88. (Pubitemid 351623887)
9. Morley JE, Kaiser FE. Sexual function with advancing age. Med Clin North Am 1989; 73: 1483-95. (Pubitemid 19285148)
10. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ et al. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983; 57: 71-7. (Pubitemid 13065447)
11. Ahn HS, Park CM, Lee SW. The clinical relevance of sex hormone levels and sexual activity in the ageing male. BJU Int 2002; 89: 526-30. (Pubitemid 34948292)
12. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983; 12: 59-66. (Pubitemid 13125331)
13. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979; 48: 955-8. (Pubitemid 9190846)
14. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793-6. (Pubitemid 27509374)
15. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab 2002; 87: 1467-72. (Pubitemid 34615223)
16. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983; 57: 557-62. (Pubitemid 13005522)
17. Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13: 297-304.
18. Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J Clin Psychopharmacol 1999; 19: 19-27. (Pubitemid 29047327)
19. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000; 57: 141-7. (Pubitemid 30075264)
20. Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 1999; 15: 131-42. (Pubitemid 29396821)
21. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299: 39-52.
22. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999; 84: 573-7. (Pubitemid 29075686)
23. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997; 12: 1833-43. (Pubitemid 27500195)
24. Khosla S, Melton LJ 3rd, Atkinson EJ, OFallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86: 3555-61. (Pubitemid 32755943)
25. Khosla S, Melton LJ 3rd, Atkinson EJ, OFallon WM, Klee GG et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266-74. (Pubitemid 28503012)
26. Drinka PJ, Bauwens SF. Male osteopenia: a brief review. J Am Geriatr Soc 1987; 35: 258-61. (Pubitemid 17038077)
27. Seeman E, Melton LJ 3rd, OFallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med 1983; 75: 977-83. (Pubitemid 14204589)
28. Smith DA, Walker MS. Changes in plasma steroids and bone density in Klinefelters syndrome. Calcif Tissue Res 1977; 22 (Suppl): 225-8.
29. Jackson JA, RiggsMW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 1992; 304: 4-8.
30. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000; 97: 4279-84. (Pubitemid 30226124)
31. Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin Endocrinol (Oxf) 1999; 50: 629-35. (Pubitemid 29236340)
32. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56: M266-72. (Pubitemid 32381803)
33. Sih R, Morley JE, Kaiser FE, PerryHM3rd, Patrick P et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-7. (Pubitemid 127495166)
34. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-72. (Pubitemid 30647018)
35. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-7. (Pubitemid 32269134)
36. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123-36. (Pubitemid 29138849)
37. Abbasi AA, Mattson DE, Duthie EH Jr, Wilson C, Sheldahl L et al. Predictors of lean body mass and total adipose mass in community-dwelling elderly men and women.Am J Med Sci 1998; 315: 188-93. (Pubitemid 28125607)
38. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002; 282: E601-7. (Pubitemid 34654776)
39. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3469-75. (Pubitemid 26339901)
40. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; 88: 2673-81. (Pubitemid 36724441)
41. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3654-62. (Pubitemid 26339933)
42. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003; 58: 618-25. (Pubitemid 36900168)
43. Wong FH, Pun KK, Wang C. Loss of bone mass in patients with Klinefelters syndrome despite sufficient testosterone replacement. Osteoporos Int 1993; 3: 3-7. (Pubitemid 23041202)
44. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386-90. (Pubitemid 27337844)
45. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-93. (Pubitemid 41233445)
46. Nair KS, Rizza RA, OBrien P, Dhatariya K, Short KR et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355: 1647-59. (Pubitemid 44583955)
47. Griggs RC, Kingston W, Jozefowicz RF, Herr BE, Forbes G et al. Effect of testosterone on muscle mass and muscle protein synthesis. J Appl Physiol 1989; 66: 498-503. (Pubitemid 19056118)
48. Kennedy BJ, Gilbertsen AS. Increased erythropoiesis induced by androgenic-hormone therapy. N Engl J Med 1957; 256: 719-26.
49. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89: 5429-34. (Pubitemid 39518421)
50. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007; 4: 497-501. (Pubitemid 46394724)
51. Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 1992; 75: 1503-7. (Pubitemid 23001411)
52. Kawa G, Taniguchi H, Kinoshita H, Matsuda K. Analysis of the statues of patients visiting our specialized clinic for hypogonadal men: 5-year experience. Hinyokika Kiyo 2009; 55: 87-92.
53. Amano T, Imao T, Takemae K, Iwamoto T, Yamakawa K et al. Profile of serum testosterone levels after application of testosterone ointment (glowmin) and its clinical efficacy in late-onset hypogonadism patients. J Sex Med 2008; 5: 1727-36. (Pubitemid 352044429)
54. Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. J Urol 2005; 173: 2072-5. (Pubitemid 40675246)
55. Tsujimura A, Matsumiya K, Takao T, Miyagawa Y, Takada S et al. Treatment with human chorionic gonadotropin for PADAM: a preliminary report. Aging Male 2005; 8: 175-9. (Pubitemid 43068308)
56. Amano T, Imao T, Takemae K, Iwamoto T, Nakanome M. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male 2010; 13: 242-6.
57. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005; 48: 1-4. (Pubitemid 40835584)
58. Tsujimura A, Takada S, Matsuoka Y, Hirai T, Takao T et al. Is discontinuation of hormone replacement therapy possible for patients with late-onset hypogonadism? Int J Urol 2008; 7: 625-9. (Pubitemid 351989336)
59. Funahashi T, Matsuzawa Y. Metabolic syndrome: clinical concept and molecular basis. Ann Med 2007; 39: 482-94. (Pubitemid 350035569)
60. Spark RF. Testosterone, diabetes mellitus, and the metabolic syndrome. Curr Urol Rep 2007; 8: 467-71. (Pubitemid 350144525)
61. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-23. (Pubitemid 40686299)
62. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-41. (Pubitemid 38579762)
63. Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L et al. The metabolic syndrome is frequent in Klinefelters syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 2006; 29: 1591-8. (Pubitemid 44127586)
64. Corona G, Mannucci E, Schulman C, Petrone L, Mansani R et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 2006; 50: 595-604. (Pubitemid 44189051)
65. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-8.
66. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7. (Pubitemid 36606394)
67. Katabami T, Kato H, Asahina T, Hinohara S, Shin T et al. Serum free testosterone and metabolic syndrome in Japanese men. Endocr J 2010; 57: 533-9.
68. Akishita M, Fukai S, Hashimoto M, Kameyama Y, Nomura K et al. Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res 2010; 33: 587-91.
69. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89: 2563-8. (Pubitemid 38766332)
70. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975-81. (Pubitemid 39540124)
71. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-41. (Pubitemid 34970926)
72. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 2004; 60: 500-7. (Pubitemid 38482514)
73. Tsujimura A, Takada S, Matsuoka Y, Nakayama J, Takao T et al. Adiponectin and testosterone in patients with symptoms of late-onset hypogonadism: is there a link? Int J Urol 2009; 16: 830-5.
74. Host C, Bojesen A, Frystyk J, Flyvbjerg A, Christiansen JS et al. Effect of sex hormone treatment on circulating adiponectin and subforms in Turner and Klinefelter syndrome. Eur J Clin Invest 2010; 40: 211-9.
75. Miwa Y, Kaneda T, Yokoyama O. Correlation between the Aging Males Symptoms Scale and sex steroids, gonadotropins, dehydroepiandrosterone sulfate, and growth hormone levels in ambulatory men. J Sex Med 2006; 3: 723-6.
76. Tsujimura A, Matsumiya K, Miyagawa Y, Takao T, Fujita K et al. Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res 2005; 17: 259-63. (Pubitemid 40675509)
77. Heinemann LA, Zimmermann T, Vermeulen A, Thiel C. A new aging males symptoms (AMS) rating scale. Aging Male 1999; 2: 105-14. (Pubitemid 29411279)
78. TSjoen G, Goemaere S, de Meyere M, Kaufman JM. Perception of males aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology 2004; 29: 201-14. (Pubitemid 37357179)
79. TSjoen G, Feyen E, de Kuyper P, Comhaire F, Kaufman JM. Self-referred patients in an aging male clinic: much more than androgen deficiency alone. Aging Male 2003; 6: 157-65. (Pubitemid 37411886)
80. Araujo AB, Esche GR, Kupelian V, ODonnell AB, Travison TG et al. Prevalence of symptomatic androgen deficiency inmen. J Clin Endocrinol Metab 2007; 92: 4241-7. (Pubitemid 350074738)
81. Chen JT, Shiraki M. Menopausal hot flash and calciotonin gene-related peptide; effect of Keishi-bukuryo-gan, a kampo medicine, related to plasma calciotonin gene-related peptide level. Maturitas 2003; 45: 199-204. (Pubitemid 36724875)
82. Ushiroyama T, Ikeda A, Sakuma K, Ueki M. Changes in serum tumor necrosis factor (TNF-alpha) with kami-shoyo-san administration in depressed climacteric patients. Am J Chin Med 2004; 32: 621-9. (Pubitemid 39302679)
83. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003;(1):CD003383.
84. Brattstrom A. Long-term effects of St. Johns wort Hypericum perforatum treatment: a 1-year safety study inmild tomoderate depression. Phytomedicine 2009; 16: 277-83.
85. Mannel M, Kuhn U, Schmidt U, Ploch M, Murck H. St. Johns wort xtract LI160 for the treatment of depression with atypical features-a double-blind, randomized, and placebo-controlled trial. J Psychiatr Res 2010; 44: 760-7.
86. Tsujimura A, Takada S, Matsuoka Y, Nakayama J, Takao T et al. Clinical trial of treatment with saikokaryukotsuboreito for eugonadal patients with late-inset hypogonadism-related symptoms. Aging Male 2008; 11: 95-9. (Pubitemid 351878780)
87. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407-18. (Pubitemid 29392689)
88. Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M et al. Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry 1994; 35: 42-7. (Pubitemid 24063274)
89. Tsujimura A, Miyagawa Y, Okuda H, Yamamoto K, Fukuhara S et al. Change in cytokine levels after administration of saikokaryuukotsuboreito or testosterone in patients with symptoms of late-onset hypogonadism. Aging Male 2011; 14: 76-81.
90. Amano T, Imao T, Takemae K. Clinical efficacy of Japanese traditional herbal medicine (Kampo) in patients with late-onset hypogonadism. Aging Male 2010; 13: 166-73.